1. Adelaide Research & Scholarship

Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 19 (Search time: 0.005 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
1995A direct analysis of FACS-sorted hemopoietic cell fractions using fishWhite, D.; Hutchins, C.; Haylock, D.; Turczynowics, S.; Bishop, A.; To, L.; Hughes, T.; Juttner, C.
1997Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.Hughes, T.; Grigg, A.; Szer, J.; Ho, J.; Ma, D.; Dale, B.; Green, R.; Norman, J.; Sage, R.; Herrmann, R.; Cannell, P.; Schwarer, A.; Taylor, K.; Atkinson, K.; Arthur, C.
2012Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?Yeung, D.; Branford, S.
2023Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment interventionShanmuganathan, N.; Wadham, C.; Shahrin, N.; Feng, J.; Thomson, D.; Wang, P.; Saunders, V.; Kok, C.H.; King, R.M.; Kenyon, R.R.; Lin, M.; Pagani, I.S.; Ross, D.M.; Yong, A.S.M.; Grigg, A.P.; Mills, A.K.; Schwarer, A.P.; Braley, J.; Altamura, H.; Yeung, D.T.; et al.
2021Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemiaOchi, Y.; Yoshida, K.; Huang, Y.-J.; Kuo, M.-C.; Nannya, Y.; Sasaki, K.; Mitani, K.; Hosoya, N.; Hiramoto, N.; Ishikawa, T.; Branford, S.; Shanmuganathan, N.; Ohyashiki, K.; Takahashi, N.; Takaku, T.; Tsuchiya, S.; Kanemura, N.; Nakamura, N.; Ueda, Y.; Yoshihara, S.; et al.
2014Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyHughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G.
2016Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patientsDeininger, M.; Hodgson, J.; Shah, N.; Cortes, J.; Kim, D.; Nicolini, F.; Talpaz, M.; Baccarani, M.; Müller, M.; Li, J.; Parker, W.; Lustgarten, S.; Clackson, T.; Haluska, F.; Guilhot, F.; Kantarjian, H.; Soverini, S.; Hochhaus, A.; Hughes, T.; Rivera, V.; et al.
2015BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phaseHughes, T.; Saglio, G.; Quintás-Cardama, A.; Mauro, M.; Kim, D.; Lipton, J.; Bradley-Garelik, M.; Ukropec, J.; Hochhaus, A.
2011OCT-1 as a determinant of response to antileukemic treatmentEngler, J.; Hughes, T.; White, D.
2003Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaO'Brien, S.; Guilhot, F.; Larson, R.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J.; Kantarjian, H.; et al.

Discover